# Ovarian cancer

Source: https://onco.cc/cancers/ovarian/  
OnCo record `ovarian` (Cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease.

## Summary

Ovarian cancer is a group of diseases (~320,000 new cases a year) dominated by high-grade serous carcinoma, which arises in the fallopian tube, is almost always TP53-mutant, and is diagnosed at stage III-IV in three-quarters of women because there is no symptom or screening test that catches it early. Roughly half of high-grade serous tumours have homologous recombination deficiency, including ~20% with germline or somatic BRCA1/2 mutations. Low-grade serous, endometrioid, clear-cell, and mucinous carcinomas are biologically distinct and respond differently to treatment.

The standard of care is maximal cytoreductive surgery (primary or interval, after neoadjuvant carboplatin-paclitaxel), sometimes with HIPEC, followed by maintenance therapy chosen by biomarker: olaparib for BRCA-mutated disease (SOLO-1, 7-year OS 67% vs 47%), olaparib plus bevacizumab for HRD-positive disease (PAOLA-1), niraparib for the rest with declining enthusiasm after PRIMA showed no survival gain. Platinum-sensitive relapse is treated with platinum doublets and secondary surgery in selected patients (DESKTOP III); PARP inhibitors are re-used less since later-line safety signals. Platinum-resistant disease, historically the hardest setting, now has three new options with survival benefit: mirvetuximab soravtansine for FRα-high tumours (MIRASOL), relacorilant plus nab-paclitaxel (ROSELLA, approved 2026), and pembrolizumab plus weekly paclitaxel for PD-L1-positive tumours (KEYNOTE-B96, approved February 2026, the first immunotherapy in ovarian cancer). Low-grade serous carcinoma gained its first dedicated therapy in avutometinib plus defactinib (2025).

What comes next: folate-receptor ADCs that work regardless of expression level (rinatabart sesutecan, luveltamab tazevibulin), a CDH6 ADC (raludotatug deruxtecan) in phase 3, ATR and WEE1 inhibitors for PARP-resistant disease, and prevention by opportunistic salpingectomy now that the tubal origin is accepted. Screening remains unsolved after UKCTOCS; multi-cancer blood tests are the only live hope.

## Fields

- Kind: Cancer
- Last checked: 2026-09-07
- Also known as: OV; TCGA-OV; ovarian serous cystadenocarcinoma (TCGA OV cohort); Fallopian Tube Cancer; Primary Peritoneal Cancer
- Tags: gyn; spike
- Group: gynaecologic
- Burden: Ovarian cancer accounts for ~320,000 cases per year worldwide. PARP-inhibitor maintenance has turned BRCA-mutated disease into one where two-thirds of women are alive at seven years, and three new treatments that extend life arrived for platinum-resistant disease in three years. Because most cases are found at stage III-IV, it remains the gynaecologic cancer with the lowest survival: 5-year survival ~50% overall and under 30% for stage IV; ~200,000 deaths per year.
- Subtypes: High-grade serous carcinoma (~70%; TP53-mutant, tubal origin); Low-grade serous carcinoma (~5%; KRAS/BRAF, ER+, chemoresistant); Endometrioid carcinoma (~10%; often with endometriosis; CTNNB1, PTEN, MMR); Clear-cell carcinoma (~10%; ARID1A, PIK3CA; platinum-resistant; higher in East Asia); Mucinous carcinoma (~3%; KRAS, HER2 amplification; often gastrointestinal-like); Carcinosarcoma and other rare types; Germ-cell and sex-cord stromal tumours (young women; highly curable)
- Biomarkers: BRCA1/2 (germline and somatic); HRD (myChoice); FRα IHC; CDH6; CA-125; PD-L1; Germline and somatic BRCA1/2; HRD genomic instability score (myChoice CDx, FoundationOne); Folate receptor alpha IHC (≥75% of cells at 2+ for mirvetuximab); PD-L1 CPS ≥1 (pembrolizumab, KEYNOTE-B96); KRAS/BRAF/NRAS (low-grade serous); CA-125 and HE4 (monitoring, ROMA index); Platinum-free interval (defines sensitive vs resistant); MMR/MSI (endometrioid, clear-cell); HER2 (mucinous, some clear-cell)

## Sections of this record

The page is a hub with ten sections in reading order; large sections have their own page. The same plan as JSON: https://onco.cc/api/v1/cancers/ovarian/sections.json

- Overview (on the hub): The TL;DR, the family this cancer belongs to, the organ, who gets it and what the state of the art is. https://onco.cc/cancers/ovarian/#overview [7 subtypes, 8 state-of-the-art points]
- What it is (on the hub): Anatomy, the subtypes and how they differ, how it is staged, and where advanced disease spreads. https://onco.cc/cancers/ovarian/#what-it-is [14 subtypes, 6 sites of spread]
- Finding it (on the hub): How it shows itself, how it is confirmed, what screening exists, and the biomarkers clinicians test for. https://onco.cc/cancers/ovarian/#finding-it [15 biomarkers, 11 prevalence rows]
- Treating it (on the hub): The standard of care by setting, the medicines, surgery and radiotherapy named in it, and the regimens behind them. https://onco.cc/cancers/ovarian/#treating-it [15 settings, 9 regimens, 13 decisions with options]
- Evidence (own page): Trials recruiting now, the landmark trials, the key papers and what they mean, the latest literature, and the milestones year by year. https://onco.cc/cancers/ovarian/evidence/ [166 trials, 10 key papers, 18 milestones]
- The science (own page): The molecular landscape: the targets and how often each appears, the pathways, the mechanics stages and the preclinical models. https://onco.cc/cancers/ovarian/science/ [167 targets, 10 pathways, 10 preclinical models]
- Where you are (own page): Cases by country, the UK and NHS pathway and other country lenses, and the expert centres with trials on record. https://onco.cc/cancers/ovarian/where-you-are/ [28 centres]
- Living with it (own page): The decisions you may face, the aids that walk through them, the warnings on record, the first sixty days and the questions to ask. https://onco.cc/cancers/ovarian/living-with-it/ [46 questions, 6 red cards]
- What is coming (own page): Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record. https://onco.cc/cancers/ovarian/coming/ [66 medicines, 166 trials, 19 ideas, 11 open problems]
- Data (own page): Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked. https://onco.cc/cancers/ovarian/data/ [692 connected records]

## Standard of care

- Newly diagnosed: Surgery + platinum-taxane ± bevacizumab ± HIPEC; PARP maintenance by HRD status. ([Carboplatin](https://onco.cc/drugs/carboplatin/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [HIPEC / PIPAC (intraperitoneal chemotherapy)](https://onco.cc/technologies/hipec/), [Olaparib](https://onco.cc/drugs/olaparib/), [Niraparib](https://onco.cc/drugs/niraparib/))
- Platinum-sensitive relapse: Platinum doublet + PARP maintenance; secondary cytoreduction in selected cases.
- Platinum-resistant: Mirvetuximab (FRα-high), relacorilant + nab-paclitaxel, pembrolizumab (PD-L1+), single-agent chemotherapy. ([Mirvetuximab soravtansine](https://onco.cc/drugs/mirvetuximab-soravtansine/), [Relacorilant](https://onco.cc/drugs/relacorilant/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/))
- Prevention and risk: Germline testing for all patients; risk-reducing salpingo-oophorectomy for BRCA carriers (age 35-45); opportunistic salpingectomy at pelvic surgery for average-risk women; oral contraceptives reduce risk. No population screening (UKCTOCS negative). ([Germline (hereditary) testing](https://onco.cc/technologies/germline-testing/), [Risk-reducing and opportunistic salpingectomy](https://onco.cc/technologies/risk-reducing-salpingectomy/), [Chemoprevention & risk-reducing surgery](https://onco.cc/technologies/chemoprevention/), [UKCTOCS](https://onco.cc/trials/ukctocs/))
- Newly diagnosed stage I-II: Complete surgical staging; adjuvant carboplatin-paclitaxel for high-grade or stage IC-II disease; observation for low-risk stage IA-IB grade 1-2. ([Carboplatin](https://onco.cc/drugs/carboplatin/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Robotic & minimally invasive surgery](https://onco.cc/technologies/robotic-surgery/))
- Newly diagnosed stage III-IV: surgery and chemotherapy: Primary debulking if complete resection is feasible, else 3 cycles neoadjuvant carboplatin-paclitaxel then interval debulking (with HIPEC in stage III, OVHIPEC-1) and 3 more cycles; add bevacizumab for high-risk or residual disease. ([Carboplatin](https://onco.cc/drugs/carboplatin/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [HIPEC / PIPAC (intraperitoneal chemotherapy)](https://onco.cc/technologies/hipec/), [OVHIPEC-1](https://onco.cc/trials/ovhipec-1/), [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [GOG-0218 & ICON7 (bevacizumab)](https://onco.cc/trials/gog-0218-icon7/))
- First-line maintenance, BRCA-mutated: Olaparib 2 years (SOLO-1) or olaparib + bevacizumab (PAOLA-1) or niraparib 3 years (PRIMA). ([Olaparib](https://onco.cc/drugs/olaparib/), [SOLO-1](https://onco.cc/trials/solo-1/), [PAOLA-1 / ENGOT-ov25](https://onco.cc/trials/paola-1/), [Niraparib](https://onco.cc/drugs/niraparib/), [PRIMA / ENGOT-OV26](https://onco.cc/trials/prima/))
- First-line maintenance, HRD-positive BRCA-wild-type: Olaparib + bevacizumab (PAOLA-1, OS benefit) or niraparib (PRIMA, PFS only). ([Olaparib](https://onco.cc/drugs/olaparib/), [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [PAOLA-1 / ENGOT-ov25](https://onco.cc/trials/paola-1/), [Niraparib](https://onco.cc/drugs/niraparib/), [HRD & BRCA testing](https://onco.cc/technologies/hrd-testing/), [PARP inhibitor + bevacizumab maintenance (HRD-positive)](https://onco.cc/pairings/parp-plus-bevacizumab/))
- First-line maintenance, HRD-negative: Bevacizumab continuation if started; niraparib is an option with small PFS benefit and no OS benefit (PRIMA); observation is reasonable. ([Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Niraparib](https://onco.cc/drugs/niraparib/), [PRIMA / ENGOT-OV26](https://onco.cc/trials/prima/))
- Platinum-sensitive relapse (interval >6 months): Secondary cytoreduction if AGO-score positive (DESKTOP III); platinum doublet (carboplatin with PLD, paclitaxel, or gemcitabine) ± bevacizumab; PARP maintenance if PARP-naive and BRCA/HRD-positive. ([DESKTOP III / ENGOT-ov20](https://onco.cc/trials/desktop-iii/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Pegylated liposomal doxorubicin](https://onco.cc/drugs/pegylated-liposomal-doxorubicin/), [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Olaparib](https://onco.cc/drugs/olaparib/), [Niraparib](https://onco.cc/drugs/niraparib/), [Rucaparib](https://onco.cc/drugs/rucaparib/))
- Platinum-resistant relapse, FRα-high: Mirvetuximab soravtansine (MIRASOL, OS benefit) with ophthalmic prophylaxis. ([Mirvetuximab soravtansine](https://onco.cc/drugs/mirvetuximab-soravtansine/), [MIRASOL / GOG-3045](https://onco.cc/trials/mirasol/), [Folate receptor alpha](https://onco.cc/targets/folr1/))
- Platinum-resistant relapse, PD-L1 CPS ≥1: Pembrolizumab + weekly paclitaxel ± bevacizumab (KEYNOTE-B96, approved Feb 2026). ([Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [KEYNOTE-B96 / ENGOT-ov65](https://onco.cc/trials/keynote-b96/))
- Platinum-resistant relapse, other: Relacorilant + nab-paclitaxel (ROSELLA, approved 2026); single-agent weekly paclitaxel, PLD, or topotecan ± bevacizumab (AURELIA); clinical trials of FRα and CDH6 ADCs. ([Relacorilant](https://onco.cc/drugs/relacorilant/), [ROSELLA / GOG-3073](https://onco.cc/trials/rosella/), [Pegylated liposomal doxorubicin](https://onco.cc/drugs/pegylated-liposomal-doxorubicin/), [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Rinatabart sesutecan](https://onco.cc/drugs/rinatabart-sesutecan/), [Raludotatug deruxtecan](https://onco.cc/drugs/raludotatug-deruxtecan/), [AURELIA](https://onco.cc/trials/aurelia/))
- Low-grade serous carcinoma: Surgery; endocrine maintenance (letrozole) after chemotherapy or instead of it; at recurrence, avutometinib + defactinib if KRAS-mutated (2025), trametinib, or endocrine therapy. ([Letrozole (and other aromatase inhibitors)](https://onco.cc/drugs/letrozole/), [Avutometinib + defactinib](https://onco.cc/drugs/avutometinib-defactinib/), [RAMP 201](https://onco.cc/trials/ramp-201/), [Low-grade serous ovarian cancer (LGSOC)](https://onco.cc/terms/lgsoc/))
- Rare histologies: Clear-cell: platinum-based therapy, trials of immunotherapy and ARID1A-directed agents; mucinous: consider GI regimens and HER2 testing; germ-cell: BEP chemotherapy with >90% cure. ([Platinum agents](https://onco.cc/technologies/platinum/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/))

## State of the art

- PARP maintenance with 7-year OS benefit in BRCA (SOLO-1).
- First ADC (mirvetuximab) with OS benefit.
- Biomarker-directed maintenance after first-line chemotherapy: olaparib for BRCA (7-year OS 67% vs 47%), olaparib + bevacizumab for HRD-positive disease.
- Three new options with overall survival benefit in platinum-resistant disease within three years: mirvetuximab (FRα-high), relacorilant + nab-paclitaxel, and pembrolizumab + paclitaxel (PD-L1-positive, first immunotherapy approval in ovarian cancer, February 2026).
- First treatment designed for low-grade serous carcinoma (avutometinib + defactinib, May 2025).
- Surgery is evidence-based at both ends: HIPEC at interval debulking adds ~12 months of survival; selected secondary cytoreduction at relapse adds ~8 months.
- Prevention by opportunistic salpingectomy is now routine policy in several countries because the tubal origin of high-grade serous cancer is accepted.
- Germline and HRD testing at diagnosis is standard and changes treatment for roughly half of patients.

## Open problems

- No effective screening.
- PARP resistance via BRCA reversion.
- Platinum-resistant disease is the hardest setting; three drugs with survival benefit arrived in 2023-26 and each adds months, so combining and sequencing them is the next step.
- Screening is unsolved: the UKCTOCS trial found no mortality reduction, so three-quarters of patients are still diagnosed at stage III-IV; opportunistic salpingectomy and multi-cancer blood tests are the live routes.
- Platinum resistance is eventually near-universal in high-grade serous disease, and each new drug adds months, not years.
- PARP inhibitor resistance (BRCA reversion, restored fork protection) has no approved counter; later-line PARP use has been curtailed by OS signals.
- Immunotherapy fails in first-line disease; benefit is confined to PD-L1-positive platinum-resistant tumours.
- Clear-cell, mucinous, and carcinosarcoma have no subtype-specific approved therapy.
- FRα-low patients are excluded from mirvetuximab; next-generation ADCs are not yet approved.
- Access to HRD testing, PARP inhibitors, and ADCs is limited outside high-income countries.
- Optimal duration of maintenance and ctDNA-guided de-escalation are untested.

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Ovarian_cancer
- Wikipedia: https://en.wikipedia.org/wiki/Ovarian_cancer

## Connected records

- pairings: [Caution: checkpoint inhibitors in first-line ovarian cancer](https://onco.cc/pairings/caution-pd1-first-line-ovarian/), [HIPEC at interval cytoreductive surgery](https://onco.cc/pairings/hipec-at-interval-surgery/), [PARP inhibitor + bevacizumab maintenance (HRD-positive)](https://onco.cc/pairings/parp-plus-bevacizumab/), [Platinum chemotherapy in HRD tumours](https://onco.cc/pairings/platinum-plus-hrd/)
- roadmaps: [ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs](https://onco.cc/roadmaps/adc-generations/)
- collections: [NHS Jewish BRCA Testing Programme](https://onco.cc/collections/nhs-jewish-brca-testing/), [Ovarian Cancer Research Alliance (OCRA)](https://onco.cc/collections/ovarian-cancer-research-alliance/), [Sharsheret](https://onco.cc/collections/sharsheret/)
- cancers: [Adult granulosa cell tumour of the ovary](https://onco.cc/cancers/granulosa-cell-tumour/), [Clear cell ovarian cancer](https://onco.cc/cancers/clear-cell-ovarian-cancer/), [Germ cell tumours of childhood and adolescence (extracranial and CNS)](https://onco.cc/cancers/paediatric-germ-cell-tumours/), [High-grade serous ovarian cancer](https://onco.cc/cancers/high-grade-serous-ovarian-cancer/), [Low-grade serous ovarian cancer](https://onco.cc/cancers/low-grade-serous-ovarian-cancer/), [Mucinous ovarian cancer](https://onco.cc/cancers/mucinous-ovarian-cancer/), [Platinum-resistant ovarian cancer](https://onco.cc/cancers/platinum-resistant-ovarian-cancer/), [Platinum-sensitive ovarian cancer](https://onco.cc/cancers/platinum-sensitive-ovarian-cancer/)
- ideas: [A functional test for homologous recombination deficiency validated across laboratories](https://onco.cc/ideas/idea-tr2-hrd-functional-standard/), [A multi-cancer platform trial of adaptive (dose-holiday) therapy](https://onco.cc/ideas/idea-bio1-adaptive-therapy-platform/), [A perpetual platform trial in every major cancer, funded as infrastructure](https://onco.cc/ideas/idea-tr2-perpetual-platforms/), [Automatic germline testing for every cancer type where it changes care](https://onco.cc/ideas/idea-prev-reflex-germline-testing/), [ctDNA-guided duration of PARP maintenance](https://onco.cc/ideas/idea-ctdna-guided-parp-duration/), [Evolution-guided 'adaptive therapy' dosing tested in randomised phase 2 trials](https://onco.cc/ideas/idea-tr1-adaptive-therapy-randomised-phase-2/), [FAPI PET as the workup for MCED positives](https://onco.cc/ideas/idea-mced-plus-fapi/), [Go back to families of women who died of ovarian cancer and offer BRCA testing](https://onco.cc/ideas/idea-prev-traceback-deceased-probands/), [Group trials by broken mechanism, not by organ or single mutation](https://onco.cc/ideas/idea-bio2-mechanism-defined-baskets/), [Is aneuploidy itself a druggable vulnerability?](https://onco.cc/ideas/idea-targeting-aneuploidy/), [Make every cold tumour hot: a coordinated programme to reprogramme immune-excluded tumours](https://onco.cc/ideas/idea-moon-cold-to-hot-programme/), [Oncology teams order germline tests; tele-genetic counsellors handle the results](https://onco.cc/ideas/idea-acc-mainstream-tele-genetic-counselling/), [One-two punch: clear senescent cells after chemotherapy](https://onco.cc/ideas/idea-senolytics-after-chemo/), [Population germline screening for hereditary cancer genes with cascade testing](https://onco.cc/ideas/idea-moon-population-germline-screening/), [Remove the fallopian tubes during any pelvic surgery once childbearing is finished](https://onco.cc/ideas/idea-prev-opportunistic-salpingectomy-default/), [Sequence folate-receptor ADCs by payload class](https://onco.cc/ideas/idea-fra-adc-sequencing-ovarian/), [Treat the body cavity, not the bloodstream, for surface spread](https://onco.cc/ideas/idea-bio2-intracavitary-immunotherapy/), [Turn chromosomal chaos into a weakness with KIF18A inhibitors](https://onco.cc/ideas/idea-bio1-cin-vulnerability-kif18a/), [Which patients' blood clones will become leukaemia after treatment?](https://onco.cc/ideas/idea-chip-risk-modifiers/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Astatine-211 alpha therapy](https://onco.cc/technologies/astatine-211-alpha-therapy/), [ATR and CHK1 inhibitors](https://onco.cc/technologies/atr-chk1-inhibitors/), [Cancer neuroscience: cutting the nerve supply](https://onco.cc/technologies/nerve-tumour-denervation/), [Chemoprevention & risk-reducing surgery](https://onco.cc/technologies/chemoprevention/), [Enteral and parenteral nutrition support](https://onco.cc/technologies/enteral-parenteral-nutrition/), [Generic sterile injectables (the 2023 platinum shortage)](https://onco.cc/technologies/sterile-injectable-generics-manufacturing/), [Germline (hereditary) testing](https://onco.cc/technologies/germline-testing/), [Hand-held and point-of-care ultrasound](https://onco.cc/technologies/hand-held-ultrasound/), [High-dose intravenous vitamin C](https://onco.cc/technologies/high-dose-vitamin-c/), [HIPEC / PIPAC (intraperitoneal chemotherapy)](https://onco.cc/technologies/hipec/), [HIPEC perfusion pumps and PIPAC nebulisers](https://onco.cc/technologies/hipec-pipac-devices/), [HRD & BRCA testing](https://onco.cc/technologies/hrd-testing/), [HRD genomic scar scores (GIS, LOH, HRDetect)](https://onco.cc/technologies/hrd-genomic-scar-scores/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Intraoperative fluorescence and Cerenkov imaging systems (SPY, Firefly, LumiSystem, LightPath)](https://onco.cc/technologies/intraoperative-fluorescence-imaging-systems/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/), [PARP inhibitors](https://onco.cc/technologies/parp-inhibitor/), [PARP PET](https://onco.cc/technologies/parp-pet/), [Parsortix label-free circulating tumour cell harvest](https://onco.cc/technologies/parsortix-ctc-harvest/), [Platinum agents](https://onco.cc/technologies/platinum/), [RAD51 foci assay (functional HRD test)](https://onco.cc/technologies/rad51-foci-assay/), [Risk-reducing and opportunistic salpingectomy](https://onco.cc/technologies/risk-reducing-salpingectomy/), [Robotic & minimally invasive surgery](https://onco.cc/technologies/robotic-surgery/), [Scalp cooling (cold caps: DigniCap, Paxman)](https://onco.cc/technologies/scalp-cooling/), [Serum tumour markers: proper use and misuse](https://onco.cc/technologies/serum-tumour-markers/), [Synthetic lethality approaches](https://onco.cc/technologies/synthetic-lethality-approaches/), [Ultrasound](https://onco.cc/technologies/ultrasound/)
- targets: [ABCB1](https://onco.cc/targets/abcb1/), [ABCG2](https://onco.cc/targets/abcg2/), [ACKR3](https://onco.cc/targets/ackr3/), [ACTL6A](https://onco.cc/targets/actl6a/), [ARHGAP35](https://onco.cc/targets/arhgap35/), [ARID2](https://onco.cc/targets/arid2/), [ASNS](https://onco.cc/targets/asns/), [ASS1](https://onco.cc/targets/ass1/), [ATM](https://onco.cc/targets/atm/), [ATP7B](https://onco.cc/targets/atp7b/), [ATR](https://onco.cc/targets/atr/), [ATRX](https://onco.cc/targets/atrx/), [AURKA](https://onco.cc/targets/aurka/), [B7-H4 (VTCN1)](https://onco.cc/targets/b7h4/), [BARD1](https://onco.cc/targets/bard1/), [BLM](https://onco.cc/targets/blm/), [BMPR1A](https://onco.cc/targets/bmpr1a/), [BRCA1 / BRCA2 (HRD)](https://onco.cc/targets/brca/), [BRIP1](https://onco.cc/targets/brip1/), [BUB1B](https://onco.cc/targets/bub1b/), [C11orf65](https://onco.cc/targets/c11orf65/), [CARD11](https://onco.cc/targets/card11/), [CBL](https://onco.cc/targets/cbl/), [CCND1](https://onco.cc/targets/ccnd1/), [CCNE1](https://onco.cc/targets/ccne1/), [CD44](https://onco.cc/targets/cd44/), [CDH1](https://onco.cc/targets/cdh1/), [CDH6](https://onco.cc/targets/cdh6/), [CDK12](https://onco.cc/targets/cdk12/), [CDKN2A](https://onco.cc/targets/cdkn2a/), [CHEK2](https://onco.cc/targets/chek2/), [Claudin 6](https://onco.cc/targets/cldn6/), [CTNNB1](https://onco.cc/targets/ctnnb1/), [CTNND2](https://onco.cc/targets/ctnnd2/), [DICER1](https://onco.cc/targets/dicer1/), [DROSHA](https://onco.cc/targets/drosha/), [ELL](https://onco.cc/targets/ell/), [EMSY](https://onco.cc/targets/emsy/), [EpCAM](https://onco.cc/targets/epcam/), [EphA2 receptor](https://onco.cc/targets/epha2/), [ERCC1](https://onco.cc/targets/ercc1/), [ERCC2](https://onco.cc/targets/ercc2/), [ERCC3](https://onco.cc/targets/ercc3/), [ERCC5](https://onco.cc/targets/ercc5/), [EXT1](https://onco.cc/targets/ext1/), [EXT2](https://onco.cc/targets/ext2/), [FAK (PTK2)](https://onco.cc/targets/fak/), [FANCA](https://onco.cc/targets/fanca/), [FANCC](https://onco.cc/targets/fancc/), [FANCD2](https://onco.cc/targets/fancd2/), [FANCM](https://onco.cc/targets/fancm/), [FBXO11](https://onco.cc/targets/fbxo11/), [FGF19](https://onco.cc/targets/fgf19/), [FGFR4](https://onco.cc/targets/fgfr4/), [FHIT](https://onco.cc/targets/fhit/), [FNTB](https://onco.cc/targets/fntb/), [Folate receptor alpha](https://onco.cc/targets/folr1/), [FOXL2](https://onco.cc/targets/foxl2/), [FOXO1](https://onco.cc/targets/foxo1/), [FOXP1](https://onco.cc/targets/foxp1/), [GADD45A](https://onco.cc/targets/gadd45a/), [GPC5](https://onco.cc/targets/gpc5/), [GSTP1](https://onco.cc/targets/gstp1/), [HGF](https://onco.cc/targets/hgf/), [HNF1A](https://onco.cc/targets/hnf1a/), [HNF1B](https://onco.cc/targets/hnf1b/), [IGF2](https://onco.cc/targets/igf2/), [KAT6A](https://onco.cc/targets/kat6a/), [KDM5C](https://onco.cc/targets/kdm5c/), [KRAS](https://onco.cc/targets/kras/), [LATS1](https://onco.cc/targets/lats1/), [LCK](https://onco.cc/targets/lck/), [LILRB2 (ILT4)](https://onco.cc/targets/lilrb2/), [MAP3K1](https://onco.cc/targets/map3k1/), [MECOM](https://onco.cc/targets/mecom/), [Mesothelin](https://onco.cc/targets/mesothelin/), [MITF](https://onco.cc/targets/mitf/), [MLH1](https://onco.cc/targets/mlh1/), [MLLT10](https://onco.cc/targets/mllt10/), [MRE11](https://onco.cc/targets/mre11/), [MSH2](https://onco.cc/targets/msh2/), [MSH6](https://onco.cc/targets/msh6/), [MUC16 (CA-125)](https://onco.cc/targets/muc16/), [MUS81](https://onco.cc/targets/mus81/), [MUTYH](https://onco.cc/targets/mutyh/), [MYH9](https://onco.cc/targets/myh9/), [NBEA](https://onco.cc/targets/nbea/), [NBN](https://onco.cc/targets/nbn/), [NF2](https://onco.cc/targets/nf2/), [NRG1](https://onco.cc/targets/nrg1/), [NUTM1](https://onco.cc/targets/nutm1/), [PALB2](https://onco.cc/targets/palb2/), [PARP](https://onco.cc/targets/parp/), [PARP2](https://onco.cc/targets/parp2/), [PARP3](https://onco.cc/targets/parp3/), [PD-1](https://onco.cc/targets/pd1/), [PD-L1](https://onco.cc/targets/pdl1/), [PIK3CB](https://onco.cc/targets/pik3cb/), [PIK3R1](https://onco.cc/targets/pik3r1/), [PMS2](https://onco.cc/targets/pms2/), [POLA2](https://onco.cc/targets/pola2/), [POLD1](https://onco.cc/targets/pold1/), [POLD2](https://onco.cc/targets/pold2/), [POLD3](https://onco.cc/targets/pold3/), [POLD4](https://onco.cc/targets/pold4/), [POLE](https://onco.cc/targets/pole/), [POLE2](https://onco.cc/targets/pole2/), [POLE3](https://onco.cc/targets/pole3/), [POLQ](https://onco.cc/targets/polq/), [PPM1D](https://onco.cc/targets/ppm1d/), [PPP2R1A](https://onco.cc/targets/ppp2r1a/), [PRAME](https://onco.cc/targets/prame/), [PRDM1](https://onco.cc/targets/prdm1/), [PREX2](https://onco.cc/targets/prex2/), [PRIM1](https://onco.cc/targets/prim1/), [PRIM2](https://onco.cc/targets/prim2/), [PRKN](https://onco.cc/targets/prkn/), [PTPRB](https://onco.cc/targets/ptprb/), [PTPRD](https://onco.cc/targets/ptprd/), [PTPRT](https://onco.cc/targets/ptprt/), [PVRIG (CD112R)](https://onco.cc/targets/pvrig/), [RAD50](https://onco.cc/targets/rad50/), [RAD51B](https://onco.cc/targets/rad51b/), [RAD51C](https://onco.cc/targets/rad51c/), [RAD51D](https://onco.cc/targets/rad51d/), [RECQL4](https://onco.cc/targets/recql4/), [REL](https://onco.cc/targets/rel/), [RNF43](https://onco.cc/targets/rnf43/), [RRAS2](https://onco.cc/targets/rras2/), [RRM2](https://onco.cc/targets/rrm2/), [RRM2B](https://onco.cc/targets/rrm2b/), [RUNX1](https://onco.cc/targets/runx1/), [SDHA](https://onco.cc/targets/sdha/), [SDHAF2](https://onco.cc/targets/sdhaf2/), [SETD1B](https://onco.cc/targets/setd1b/), [SMARCA4](https://onco.cc/targets/smarca4/), [SMARCB1](https://onco.cc/targets/smarcb1/), [SPOP](https://onco.cc/targets/spop/), [STAT1](https://onco.cc/targets/stat1/), [STAT3](https://onco.cc/targets/stat3/), [STK11](https://onco.cc/targets/stk11/), [SYK](https://onco.cc/targets/syk/), [TERT](https://onco.cc/targets/tert/), [TET1](https://onco.cc/targets/tet1/), [Thioredoxin reductase 1](https://onco.cc/targets/txnrd1/), [TNC](https://onco.cc/targets/tnc/), [TP53](https://onco.cc/targets/tp53/), [TRIM24](https://onco.cc/targets/trim24/), [Tubulin (microtubules)](https://onco.cc/targets/tubulin/), [UBR5](https://onco.cc/targets/ubr5/), [VEGF / VEGFR](https://onco.cc/targets/vegf/), [VPS37A](https://onco.cc/targets/vps37a/), [WEE1](https://onco.cc/targets/wee1/), [WWTR1](https://onco.cc/targets/wwtr1/), [ZNF217](https://onco.cc/targets/znf217/), [ZNF521](https://onco.cc/targets/znf521/)
- drugs: [Altretamine](https://onco.cc/drugs/altretamine/), [Amifostine](https://onco.cc/drugs/amifostine/), [Anetumab ravtansine](https://onco.cc/drugs/anetumab-ravtansine/), [Avutometinib + defactinib](https://onco.cc/drugs/avutometinib-defactinib/), [AVZO-021](https://onco.cc/drugs/avzo-021/), [AZD5335](https://onco.cc/drugs/azd5335/), [AZD8421](https://onco.cc/drugs/azd8421/), [Azenosertib](https://onco.cc/drugs/azenosertib/), [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [BRACAnalysis CDx](https://onco.cc/drugs/bracanalysis-cdx/), [Brenetafusp](https://onco.cc/drugs/brenetafusp/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Catumaxomab](https://onco.cc/drugs/catumaxomab/), [Chiauranib](https://onco.cc/drugs/chiauranib/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [CYH33](https://onco.cc/drugs/cyh33/), [Galleri](https://onco.cc/drugs/galleri/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Gotistobart](https://onco.cc/drugs/gotistobart/), [HLX43](https://onco.cc/drugs/hlx43/), [HS-20089](https://onco.cc/drugs/hs-20089/), [IBI354](https://onco.cc/drugs/ibi354/), [IN10018](https://onco.cc/drugs/in10018/), [INCB123667](https://onco.cc/drugs/incb123667/), [Ipatasertib](https://onco.cc/drugs/ipatasertib/), [JK08](https://onco.cc/drugs/jk08/), [Letrozole (and other aromatase inhibitors)](https://onco.cc/drugs/letrozole/), [Lorigerlimab](https://onco.cc/drugs/lorigerlimab/), [Luveltamab tazevibulin](https://onco.cc/drugs/luveltamab-tazevibulin/), [M701](https://onco.cc/drugs/m701/), [Melphalan (including hepatic delivery system)](https://onco.cc/drugs/melphalan/), [Mirvetuximab soravtansine](https://onco.cc/drugs/mirvetuximab-soravtansine/), [myChoice CDx](https://onco.cc/drugs/mychoice-cdx/), [Niraparib](https://onco.cc/drugs/niraparib/), [NUV-1511](https://onco.cc/drugs/nuv-1511/), [Olaparib](https://onco.cc/drugs/olaparib/), [Olvimulogene nanivacirepvec](https://onco.cc/drugs/olvimulogene-nanivacirepvec/), [Oregovomab](https://onco.cc/drugs/oregovomab/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Pafolacianine](https://onco.cc/drugs/pafolacianine/), [Palacaparib](https://onco.cc/drugs/palacaparib/), [Pamiparib](https://onco.cc/drugs/pamiparib/), [Pegylated liposomal doxorubicin](https://onco.cc/drugs/pegylated-liposomal-doxorubicin/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [PF-08634404](https://onco.cc/drugs/pf-08634404/), [Puxitatug samrotecan](https://onco.cc/drugs/puxitatug-samrotecan/), [Raludotatug deruxtecan](https://onco.cc/drugs/raludotatug-deruxtecan/), [Relacorilant](https://onco.cc/drugs/relacorilant/), [Rinatabart sesutecan](https://onco.cc/drugs/rinatabart-sesutecan/), [Rucaparib](https://onco.cc/drugs/rucaparib/), [Saruparib](https://onco.cc/drugs/saruparib/), [Senaparib (IMP4297)](https://onco.cc/drugs/imp4927/), [SHR-A1921](https://onco.cc/drugs/shr-a1921/), [Sofetabart Mipitecan](https://onco.cc/drugs/sofetabart-mipitecan/), [Talc (intrapleural)](https://onco.cc/drugs/talc-sclerosant/), [THEO-260](https://onco.cc/drugs/theo-260/), [Thiotepa](https://onco.cc/drugs/thiotepa/), [TILT-123](https://onco.cc/drugs/tilt-123/), [Topotecan](https://onco.cc/drugs/topotecan/), [Trabectedin](https://onco.cc/drugs/trabectedin/), [Ubamatamab](https://onco.cc/drugs/ubamatamab/), [Upifitamab rilsodotin](https://onco.cc/drugs/upifitamab-rilsodotin/), [Utomilumab](https://onco.cc/drugs/utomilumab/), [VB15010](https://onco.cc/drugs/vb15010/), [Vudalimab](https://onco.cc/drugs/vudalimab/), [XNW27011](https://onco.cc/drugs/xnw27011/)
- companies: [A2 Biotherapeutics](https://onco.cc/companies/a2-biotherapeutics/), [AbbVie (incl. ImmunoGen, Capstan)](https://onco.cc/companies/abbvie/), [Acrivon Therapeutics](https://onco.cc/companies/acrivon-therapeutics/), [AGO Study Group](https://onco.cc/companies/ago-study-group/), [ANGLE plc](https://onco.cc/companies/angle-plc/), [AOA Dx](https://onco.cc/companies/aoa-dx/), [ARCAGY-GINECO](https://onco.cc/companies/arcagy-gineco/), [Arsenal Biosciences](https://onco.cc/companies/arsenal-bio/), [Artios Pharma](https://onco.cc/companies/artios-pharma/), [AstraZeneca](https://onco.cc/companies/astrazeneca/), [Belmont Medical Technologies](https://onco.cc/companies/belmont-medical-technologies/), [BioInvent International](https://onco.cc/companies/bioinvent-international/), [Capnomed (Reger Medizintechnik)](https://onco.cc/companies/capnomed/), [ClearNote Health](https://onco.cc/companies/clearnote-health/), [Clovis Oncology](https://onco.cc/companies/clovis-oncology/), [Corcept Therapeutics](https://onco.cc/companies/corcept/), [Daiichi Sankyo](https://onco.cc/companies/daiichi-sankyo/), [Debiopharm](https://onco.cc/companies/debiopharm/), [Evopoint Biosciences](https://onco.cc/companies/evopoint-biosciences/), [Fujirebio](https://onco.cc/companies/fujirebio/), [Genelux](https://onco.cc/companies/genelux/), [Generate:Biomedicines](https://onco.cc/companies/generate-biomedicines/), [Genmab](https://onco.cc/companies/genmab/), [GI Innovation](https://onco.cc/companies/gi-innovation/), [GOG Foundation](https://onco.cc/companies/gog-foundation/), [GSK](https://onco.cc/companies/gsk/), [Haihe Biopharma](https://onco.cc/companies/haihe-biopharma/), [Immunovaccine (IMV)](https://onco.cc/companies/immunovaccine/), [IMPACT Therapeutics](https://onco.cc/companies/impact-therapeutics/), [Imunon](https://onco.cc/companies/imunon/), [intoDNA](https://onco.cc/companies/intodna/), [InxMed](https://onco.cc/companies/inxmed/), [Kiyatec](https://onco.cc/companies/kiyatec/), [Kymera Therapeutics](https://onco.cc/companies/kymera/), [Mendus](https://onco.cc/companies/mendus/), [Merck & Co. (MSD)](https://onco.cc/companies/merck/), [Mersana Therapeutics](https://onco.cc/companies/mersana/), [Monte Rosa Therapeutics](https://onco.cc/companies/monte-rosa/), [MRC Clinical Trials Unit at UCL](https://onco.cc/companies/mrc-ctu/), [Myriad Genetics](https://onco.cc/companies/myriad-genetics/), [Nanjing Leads Biolabs](https://onco.cc/companies/nanjing-leads-biolabs/), [Nuvation Bio](https://onco.cc/companies/nuvation-bio/), [On Target Laboratories](https://onco.cc/companies/on-target-laboratories/), [OncoC4](https://onco.cc/companies/oncoc4/), [OSE Immunotherapeutics](https://onco.cc/companies/ose-immunotherapeutics/), [Outcomes4Me](https://onco.cc/companies/outcomes4me/), [pharma&](https://onco.cc/companies/pharmaand/), [ProfoundBio](https://onco.cc/companies/profoundbio/), [Radiopharm Theranostics](https://onco.cc/companies/radiopharm-theranostics/), [Roche / Genentech](https://onco.cc/companies/roche-genentech/), [Scancell](https://onco.cc/companies/scancell/), [Shenzhen Ionova Life Sciences](https://onco.cc/companies/shenzhen-ionova-life-sciences/), [Sutro Biopharma](https://onco.cc/companies/sutro-biopharma/), [Telik](https://onco.cc/companies/telik/), [TORL BioTherapeutics](https://onco.cc/companies/torl-biotherapeutics/), [Tradewind BioScience](https://onco.cc/companies/tradewind-bioscience/), [Tubulis (Gilead)](https://onco.cc/companies/tubulis/), [Verastem Oncology](https://onco.cc/companies/verastem/), [Xencor](https://onco.cc/companies/xencor/), [Zentalis Pharmaceuticals](https://onco.cc/companies/zentalis-pharmaceuticals/)
- pathways: [Base excision repair, PARP & alkylation damage](https://onco.cc/pathways/base-excision-repair-parp/), [DNA damage response & homologous recombination](https://onco.cc/pathways/ddr/), [Double-strand break repair: HR versus end joining](https://onco.cc/pathways/homologous-recombination-repair/), [Lipid synthesis, uptake & cholesterol](https://onco.cc/pathways/lipid-metabolism-cancer/), [Organ tropism: seed and soil](https://onco.cc/pathways/organ-tropism-seed-soil/), [p53 / RB / cell-cycle checkpoint](https://onco.cc/pathways/p53-cell-cycle/), [SWI/SNF chromatin remodelling](https://onco.cc/pathways/swi-snf-chromatin/), [The angiogenic switch & tumour vessels](https://onco.cc/pathways/angiogenic-switch/), [The cell-cycle engine (cyclins & CDKs)](https://onco.cc/pathways/cell-cycle-engine-cdks/), [The p53 network (guardian of the genome)](https://onco.cc/pathways/p53-mdm2-axis/)
- terms: [CA-125](https://onco.cc/terms/ca-125/), [Combined positive score (CPS)](https://onco.cc/terms/cps/), [Debulking (cytoreductive surgery)](https://onco.cc/terms/debulking/), [Founder mutation (BRCA1 185delAG and 5382insC, BRCA2 6174delT)](https://onco.cc/terms/founder-mutation/), [Germline BRCA mutation (gBRCA)](https://onco.cc/terms/gbrca-mutation/), [High-grade serous ovarian carcinoma (HGSOC)](https://onco.cc/terms/hgsoc/), [HIPEC (hyperthermic intraperitoneal chemotherapy)](https://onco.cc/terms/hipec-procedure/), [Intraperitoneal (IP) chemotherapy](https://onco.cc/terms/intraperitoneal-chemotherapy/), [Low-grade serous ovarian cancer (LGSOC)](https://onco.cc/terms/lgsoc/), [Maintenance therapy](https://onco.cc/terms/maintenance-therapy/), [Malignant pleural effusion and ascites](https://onco.cc/terms/pleural-effusion/), [Obesity-related cancers (IARC list of 13)](https://onco.cc/terms/obesity-related-cancers/), [Peritoneal metastasis](https://onco.cc/terms/peritoneal-metastasis/), [Peritoneum and peritoneal metastases](https://onco.cc/terms/peritoneum/), [Platinum-sensitive / platinum-resistant](https://onco.cc/terms/platinum-sensitivity/), [Risk-reducing surgery for BRCA carriers (bilateral and contralateral mastectomy, salpingo-oophorectomy)](https://onco.cc/terms/risk-reducing-surgery-brca-carriers/), [Salpingo-oophorectomy](https://onco.cc/terms/salpingo-oophorectomy/), [Synthetic lethality](https://onco.cc/terms/synthetic-lethality/), [TP53-mutated (p53-abnormal)](https://onco.cc/terms/tp53-mutated/), [Tumour marker](https://onco.cc/terms/tumour-marker/)
- trials: [[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications](https://onco.cc/trials/nct07432633/), [[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications](https://onco.cc/trials/nct07702292/), [177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors](https://onco.cc/trials/nct07189871/), [A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.](https://onco.cc/trials/nct05335993/), [A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)](https://onco.cc/trials/nct06843447/), [A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer](https://onco.cc/trials/nct06840002/), [A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer](https://onco.cc/trials/nct07714668/), [A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)](https://onco.cc/trials/nct07318558/), [A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer](https://onco.cc/trials/nct06888921/), [A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer](https://onco.cc/trials/nct03602859/), [A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With ](https://onco.cc/trials/nct06188520/), [A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors](https://onco.cc/trials/nct04686682/), [A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study](https://onco.cc/trials/nct04641247/), [A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations](https://onco.cc/trials/nct07109726/), [A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies](https://onco.cc/trials/nct05199272/), [A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In P](https://onco.cc/trials/nct06710288/), [A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.](https://onco.cc/trials/nct02734004/), [A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer](https://onco.cc/trials/nct05902988/), [A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies](https://onco.cc/trials/nct05123482/), [A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors](https://onco.cc/trials/nct06769152/), [A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANK](https://onco.cc/trials/nct06994195/), [A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors](https://onco.cc/trials/nct04931342/), [A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct04657068/), [A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer](https://onco.cc/trials/nct06072781/), [A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients](https://onco.cc/trials/nct06682572/), [A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer](https://onco.cc/trials/nct05128825/), [A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression](https://onco.cc/trials/nct07546500/), [A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.](https://onco.cc/trials/nct06434610/), [A Study of DC05F01 in Chinese Patients With Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors](https://onco.cc/trials/nct06873555/), [A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2](https://onco.cc/trials/nct06003231/), [A Study of DM002 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06751329/), [A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors](https://onco.cc/trials/nct05377996/), [A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer](https://onco.cc/trials/nct04169997/), [A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression](https://onco.cc/trials/nct07023627/), [A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer](https://onco.cc/trials/nct07042802/), [A Study of Lorigerlimab in Participants With Advanced Solid Tumors](https://onco.cc/trials/nct06730347/), [A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer Wit](https://onco.cc/trials/nct06365853/), [A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies](https://onco.cc/trials/nct06395519/), [A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery](https://onco.cc/trials/nct06504147/), [A Study of SHR-A1811 in Subjects With Ovarian Cancer](https://onco.cc/trials/nct06828354/), [A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors](https://onco.cc/trials/nct06390995/), [A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies](https://onco.cc/trials/nct05032040/), [A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primar](https://onco.cc/trials/nct06682988/), [A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult](https://onco.cc/trials/nct07059845/), [A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Fo](https://onco.cc/trials/nct06890338/), [A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN1](https://onco.cc/trials/nct07024784/), [A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients](https://onco.cc/trials/nct06522828/), [A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma](https://onco.cc/trials/nct05043922/), [A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Pl](https://onco.cc/trials/nct06824467/), [A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression](https://onco.cc/trials/nct06051695/), [A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizu](https://onco.cc/trials/nct05824975/), [A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor](https://onco.cc/trials/nct07612891/), [A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations](https://onco.cc/trials/nct07610798/), [A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamata](https://onco.cc/trials/nct04590326/), [A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)](https://onco.cc/trials/nct07286266/), [A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other](https://onco.cc/trials/nct05081609/), [A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer](https://onco.cc/trials/nct07213804/), [A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies](https://onco.cc/trials/nct04503265/), [A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer](https://onco.cc/trials/nct00880360/), [A Trial of Vigil for Participants With Ovarian Cancer](https://onco.cc/trials/nct02346747/), [ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)](https://onco.cc/trials/nct05601752/), [An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer](https://onco.cc/trials/nct06560112/), [An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Can](https://onco.cc/trials/nct07604766/), [An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer](https://onco.cc/trials/nct00532194/), [ATHENA-MONO / GOG-3020](https://onco.cc/trials/athena-mono/), [AURELIA](https://onco.cc/trials/aurelia/), [AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer](https://onco.cc/trials/nct07218809/), [Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangeme](https://onco.cc/trials/nct02568267/), [BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)](https://onco.cc/trials/nct04752826/), [Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer](https://onco.cc/trials/nct03949283/), [CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.](https://onco.cc/trials/nct06690775/), [CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ov](https://onco.cc/trials/nct07322094/), [Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cancer](https://onco.cc/trials/nct07125391/), [Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer](https://onco.cc/trials/nct04921527/), [Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer](https://onco.cc/trials/nct06686030/), [Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing](https://onco.cc/trials/nct05059522/), [D9319C00001- 1L OC Mono Global RCT](https://onco.cc/trials/nct04884360/), [DESKTOP III / ENGOT-ov20](https://onco.cc/trials/desktop-iii/), [Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer](https://onco.cc/trials/nct07589543/), [Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)](https://onco.cc/trials/nct07480954/), [Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2](https://onco.cc/trials/nct07617753/), [DUO-O / ENGOT-ov46](https://onco.cc/trials/duo-o/), [Early Phase Study of KESONOTIDE™in Participants With Solid Tumours](https://onco.cc/trials/nct06926075/), [Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)](https://onco.cc/trials/nct05281471/), [FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC](https://onco.cc/trials/nct06303505/), [First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b](https://onco.cc/trials/nct03319628/), [Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)](https://onco.cc/trials/nct05804370/), [GOG-0218 & ICON7 (bevacizumab)](https://onco.cc/trials/gog-0218-icon7/), [HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer](https://onco.cc/trials/nct06855069/), [HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer](https://onco.cc/trials/nct06014190/), [IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurren](https://onco.cc/trials/nct06014528/), [IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer](https://onco.cc/trials/nct05551507/), [Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors](https://onco.cc/trials/nct00004157/), [Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer](https://onco.cc/trials/nct03878849/), [Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer](https://onco.cc/trials/nct06787612/), [KEYNOTE-B96 / ENGOT-ov65](https://onco.cc/trials/keynote-b96/), [Lead-212 PSV359 Therapy for Patients With Solid Tumors](https://onco.cc/trials/nct06710756/), [Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer](https://onco.cc/trials/nct03519230/), [MIRASOL / GOG-3045](https://onco.cc/trials/mirasol/), [Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer](https://onco.cc/trials/nct04274426/), [Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ov](https://onco.cc/trials/nct05456685/), [Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal C](https://onco.cc/trials/nct05445778/), [Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer](https://onco.cc/trials/nct05329532/), [NHS-Galleri](https://onco.cc/trials/nhs-galleri/), [Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy](https://onco.cc/trials/nct01874353/), [ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer](https://onco.cc/trials/nct05446298/), [Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) ](https://onco.cc/trials/nct05271318/), [Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer](https://onco.cc/trials/nct05735080/), [Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer](https://onco.cc/trials/nct04938583/), [Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery](https://onco.cc/trials/nct04498117/), [Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer](https://onco.cc/trials/nct05605535/), [OVHIPEC-1](https://onco.cc/trials/ovhipec-1/), [p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246](https://onco.cc/trials/nct03268382/), [PAOLA-1 / ENGOT-ov25](https://onco.cc/trials/paola-1/), [PF-07104091 as a Single Agent and in Combination Therapy](https://onco.cc/trials/nct04553133/), [Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer](https://onco.cc/trials/nct03907852/), [Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Pat](https://onco.cc/trials/nct06915025/), [Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)](https://onco.cc/trials/nct04152499/), [Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06819215/), [Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors](https://onco.cc/trials/nct05797168/), [Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer](https://onco.cc/trials/nct05739981/), [Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer](https://onco.cc/trials/nct00563836/), [PRIMA / ENGOT-OV26](https://onco.cc/trials/prima/), [RAINFOL-01 (Rina-S)](https://onco.cc/trials/rainfol-01/), [RAMP 201](https://onco.cc/trials/ramp-201/), [Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients](https://onco.cc/trials/nct00189345/), [REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1](https://onco.cc/trials/nct05870748/), [REJOICE-Ovarian01](https://onco.cc/trials/rejoice-ovarian01/), [Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers](https://onco.cc/trials/nct06906341/), [Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib](https://onco.cc/trials/nct04421963/), [ROSELLA / GOG-3073](https://onco.cc/trials/rosella/), [Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy](https://onco.cc/trials/nct00377429/), [Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06334432/), [SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer](https://onco.cc/trials/nct06394492/), [Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy](https://onco.cc/trials/nct00716976/), [SOLO-1](https://onco.cc/trials/solo-1/), [SORAYA](https://onco.cc/trials/soraya/), [Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression](https://onco.cc/trials/nct04180371/), [Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies](https://onco.cc/trials/nct04561362/), [Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06380660/), [Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recur](https://onco.cc/trials/nct03836352/), [Study of AVZO-021 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct05867251/), [Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies](https://onco.cc/trials/nct04644068/), [Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)](https://onco.cc/trials/nct05489211/), [Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer](https://onco.cc/trials/nct06834672/), [Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)](https://onco.cc/trials/nct03393884/), [Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)](https://onco.cc/trials/nct04956640/), [Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent](https://onco.cc/trials/nct03564340/), [Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-](https://onco.cc/trials/nct06819007/), [Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer](https://onco.cc/trials/nct07736937/), [Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments](https://onco.cc/trials/nct06799637/), [Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors](https://onco.cc/trials/nct05985655/), [Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Re](https://onco.cc/trials/nct07225270/), [Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or](https://onco.cc/trials/nct07564141/), [Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer](https://onco.cc/trials/nct06619236/), [Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitax](https://onco.cc/trials/nct01081951/), [Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression](https://onco.cc/trials/nct07214779/), [Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, o](https://onco.cc/trials/nct07219238/), [Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC](https://onco.cc/trials/nct07341100/), [The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)](https://onco.cc/trials/nct04585750/), [Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)](https://onco.cc/trials/nct07109414/), [Trial of THEO-260 in Ovarian Cancer Patients](https://onco.cc/trials/nct06618235/), [UKCTOCS](https://onco.cc/trials/ukctocs/), [WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC](https://onco.cc/trials/nct04644289/), [XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.](https://onco.cc/trials/nct06792435/), [Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma](https://onco.cc/trials/nct00390234/)
- people: [Alan Ashworth](https://onco.cc/people/alan-ashworth/), [Alan D. D'Andrea](https://onco.cc/people/alan-dandrea/), [Amit M. Oza](https://onco.cc/people/amit-oza/), [Andreas du Bois](https://onco.cc/people/andreas-du-bois/), [Ane Gerda Eriksson](https://onco.cc/people/ane-gerda-eriksson/), [Angelina Jolie](https://onco.cc/people/angelina-jolie/), [Anna Fagotti](https://onco.cc/people/anna-fagotti/), [Anthony Gonçalves](https://onco.cc/people/anthony-goncalves/), [Antonio González-Martín](https://onco.cc/people/antonio-gonzalez-martin/), [Bradley J. Monk](https://onco.cc/people/bradley-monk/), [Charlie Gourley](https://onco.cc/people/charlie-gourley/), [Christian Singer](https://onco.cc/people/christian-singer/), [David M. Gershenson](https://onco.cc/people/david-gershenson/), [Domenica Lorusso](https://onco.cc/people/domenica-lorusso/), [Douglas A. Levine](https://onco.cc/people/douglas-levine/), [Evanthia Galanis](https://onco.cc/people/evanthia-galanis/), [Evelyn Lauder](https://onco.cc/people/evelyn-lauder/), [Gilda Radner](https://onco.cc/people/gilda-radner/), [Giovanni Scambia](https://onco.cc/people/giovanni-scambia/), [Ignace Vergote](https://onco.cc/people/ignace-vergote/), [Isabelle Ray-Coquard](https://onco.cc/people/isabelle-ray-coquard/), [Jalid Sehouli](https://onco.cc/people/jalid-sehouli/), [James Brenton](https://onco.cc/people/james-brenton/), [Jonathan A. Ledermann](https://onco.cc/people/jonathan-ledermann/), [Judy E. Garber](https://onco.cc/people/judy-garber/), [Kan Yonemori](https://onco.cc/people/yonemori-kan/), [Karen H. Lu](https://onco.cc/people/karen-lu/), [Kathleen N. Moore](https://onco.cc/people/kathleen-moore/), [Kunle Odunsi](https://onco.cc/people/kunle-odunsi/), [Mansoor Raza Mirza](https://onco.cc/people/mansoor-raza-mirza/), [Mary-Claire King](https://onco.cc/people/mary-claire-king/), [Matthew A. Powell](https://onco.cc/people/matthew-powell/), [Nicole Concin](https://onco.cc/people/nicole-concin/), [Nicoletta Colombo](https://onco.cc/people/nicoletta-colombo/), [Rita Schmutzler](https://onco.cc/people/rita-schmutzler/), [Robert L. Coleman](https://onco.cc/people/robert-coleman/), [Robert S. Mannel](https://onco.cc/people/robert-mannel/), [Sara Y. Brucker](https://onco.cc/people/sara-brucker/), [Sébastien Armanet](https://onco.cc/people/sebastien-armanet/), [Shannon N. Westin](https://onco.cc/people/shannon-westin/), [Sudeep Gupta](https://onco.cc/people/gupta-sudeep/), [Susan M. Domchek](https://onco.cc/people/susan-domchek/), [Susana Banerjee](https://onco.cc/people/susana-banerjee/), [Thomas Herzog](https://onco.cc/people/thomas-herzog/), [Ursula A. Matulonis](https://onco.cc/people/ursula-matulonis/), [Usha Menon](https://onco.cc/people/usha-menon/), [Willemien J. van Driel](https://onco.cc/people/willemien-van-driel/)
- key papers: [AURELIA: bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer](https://onco.cc/key-papers/paper-aurelia-bevacizumab-platinum-resistant-ovarian-pujade-lauraine-jco-2014/), [Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer](https://onco.cc/key-papers/paper-gorski-brca1-founder-mutations-poland-ajhg-2000/), [IARC verdict: excess body fat causes 13 cancers](https://onco.cc/key-papers/paper-body-fatness-iarc-nejm-2016/), [Ivermectin and gynecologic cancer: what's the data?](https://onco.cc/key-papers/paper-mujumdar-ivermectin-gynaecological-cancer-2025/), [PAOLA-1: olaparib added to bevacizumab maintenance in newly diagnosed ovarian cancer, with benefit confined to HRD-positive tumours](https://onco.cc/key-papers/paper-paola-1-nejm-2019/), [Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial](https://onco.cc/key-papers/paper-nhs-galleri-performance-nat-med-2026/), [PROSE consortium: preventive surgery lowers cancer and death in BRCA1 and BRCA2 carriers](https://onco.cc/key-papers/paper-brca-risk-reducing-surgery-jama-2010/), [Slamon 1989: HER2/neu in human breast and ovarian cancer](https://onco.cc/key-papers/paper-slamon-her2-breast-ovarian-science-1989/), [SOLO-1: two years of olaparib maintenance after first-line chemotherapy for BRCA-mutated ovarian cancer](https://onco.cc/key-papers/paper-solo-1-nejm-2018/), [The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews](https://onco.cc/key-papers/paper-struewing-brca-founder-mutations-ashkenazi-nejm-1997/)
- journals: [International journal of gynecological cancer](https://onco.cc/journals/international-journal-of-gynecological-cancer/), [Journal of gynecologic oncology](https://onco.cc/journals/journal-of-gynecologic-oncology/)
- institutions: [BC Cancer](https://onco.cc/institutions/bc-cancer/), [Cancer Research UK Cambridge Centre / CRUK Cambridge Institute](https://onco.cc/institutions/cruk-cambridge-centre/), [Centre hospitalier de l'Université de Montréal (CHUM)](https://onco.cc/institutions/chum/), [Centre Oscar Lambret](https://onco.cc/institutions/centre-oscar-lambret/), [Chris O'Brien Lifehouse](https://onco.cc/institutions/chris-obrien-lifehouse/), [Edinburgh Cancer Centre / CRUK Scotland Centre](https://onco.cc/institutions/edinburgh-cancer-centre/), [European Society of Gynaecological Oncology](https://onco.cc/institutions/esgo/), [Institut Bergonié](https://onco.cc/institutions/institut-bergonie/), [Instituto Português de Oncologia do Porto Francisco Gentil](https://onco.cc/institutions/ipo-porto/), [IRCCS Regina Elena National Cancer Institute](https://onco.cc/institutions/regina-elena-rome/), [Kliniken Essen-Mitte](https://onco.cc/institutions/kliniken-essen-mitte/), [Lausanne University Hospital (CHUV) / Ludwig Institute Lausanne](https://onco.cc/institutions/chuv-lausanne/), [Newcastle Cancer Centre / Northern Centre for Cancer Care](https://onco.cc/institutions/newcastle-cancer-centre/), [Northwell Health Cancer Institute](https://onco.cc/institutions/northwell-cancer-institute/), [O'Neal Comprehensive Cancer Center at UAB](https://onco.cc/institutions/oneal-uab/), [Ontario Institute for Cancer Research](https://onco.cc/institutions/oicr/), [Oxford Cancer (Oxford University Hospitals and University of Oxford)](https://onco.cc/institutions/oxford-cancer/), [Peking Union Medical College Hospital](https://onco.cc/institutions/pumch/), [Policlinico Universitario A. Gemelli](https://onco.cc/institutions/gemelli/), [QIMR Berghofer Medical Research Institute](https://onco.cc/institutions/qimr-berghofer/), [Shaare Zedek Medical Center](https://onco.cc/institutions/shaare-zedek/), [Society of Gynecologic Oncology](https://onco.cc/institutions/sgo/), [Stephenson Cancer Center, OU Health](https://onco.cc/institutions/stephenson-oklahoma/), [The US Oncology Network / US Oncology Research](https://onco.cc/institutions/us-oncology-network/), [The Wistar Institute](https://onco.cc/institutions/wistar/), [Tongji Hospital, Huazhong University of Science and Technology](https://onco.cc/institutions/tongji-hospital-wuhan/), [University Hospital Basel / Tumour Centre](https://onco.cc/institutions/usb-basel/), [UZ Leuven / Leuven Cancer Institute](https://onco.cc/institutions/uz-leuven/)
- bottlenecks: [Biomarkers are not validated or standardised](https://onco.cc/bottlenecks/b-biomarker-validation/), [Cold tumours and the immunosuppressive microenvironment](https://onco.cc/bottlenecks/b-tme-immunosuppression/), [Inherited risk is mostly unidentified](https://onco.cc/bottlenecks/b-hereditary-risk/), [The hardest cancers are found late](https://onco.cc/bottlenecks/b-early-detection/)
- biomarkers: [Folate receptor alpha expression (FRα-positive, PS2+ >= 75%)](https://onco.cc/biomarkers/folr1-expression/), [Germline BRCA1/2 pathogenic variant (gBRCAm)](https://onco.cc/biomarkers/brca-germline/), [HRD-positive (genomic instability score)](https://onco.cc/biomarkers/hrd-positive/), [PD-L1 CPS (combined positive score)](https://onco.cc/biomarkers/pd-l1-cps/), [TP53 mutation and del(17p)](https://onco.cc/biomarkers/tp53-del17p/), [Tumour (somatic or germline) BRCA1/2 mutation and HRR gene alterations](https://onco.cc/biomarkers/brca-somatic/)

---
JSON: https://onco.cc/api/v1/entities/ovarian.json